ABBV-744 IN COMBINATION WITH IMMUNOTHERAPY - AN OVERVIEW

In Segment C, members will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will obtain ABBV-744 and ruxolitinib. Contributors will receive treatment right up until disease progression or perhaps the contributors are not able to tolerate the study drugs.There may be higher treatment load for contributors In this particular trial when